Monday, 16 November 2026NewsWorldBusinessTech
Latest

Ziltivekimab Fails to Reduce Cardiovascular Risk in ZEUS Trial

Heart with artery view

Ziltivekimab failed to reduce the combined risk of heart attack, stroke, or cardiovascular death among 6,376 adults with advanced atherosclerotic cardiovascular disease and chronic kidney disease, according to clinical trial findings presented on November 7, 2026.